Newbridge Financial Services Group’s Praxis Precision Medicines PRAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
– Sell
-2
Closed -$39 – 1293
2023
Q3
$39 Hold
2
– – ﹤0.01% 1264
2023
Q2
$26 Hold
2
– – ﹤0.01% 1333
2023
Q1
$19 Hold
2
– – ﹤0.01% 1395
2022
Q4
$55 Hold
2
– – ﹤0.01% 1412
2022
Q3
$0 Hold
2
– – ﹤0.01% 1458
2022
Q2
$0 Hold
2
– – ﹤0.01% 1486
2022
Q1
$0 Hold
2
– – ﹤0.01% 1530
2021
Q4
$0 Hold
2
– – ﹤0.01% 1511
2021
Q3
$1K Hold
2
– – ﹤0.01% 1296
2021
Q2
$0 Hold
2
– – ﹤0.01% 1499
2021
Q1
$1K Buy
+2
New +$1.42K ﹤0.01% 1310

Other funds holding PRAX

Newbridge Financial Services Group's PRAX Position: Q4 2023 in Review

Newbridge Financial Services Group sold out of Praxis Precision Medicines (PRAX) in Q4 2023, closing a stake of 2 shares — an estimated $39 sold.

Newbridge Financial Services Group first reported a position in PRAX in Q1 2021 and held it in 11 quarters. The position peaked at $1K in Q3 2021. 60 funds tracked by Wall St. Rank hold PRAX as of Q4 2023.

  • Newbridge Financial Services Group reported no remaining Praxis Precision Medicines position as of Q4 2023 after selling out during the quarter.
  • Newbridge Financial Services Group sold 2 Praxis Precision Medicines shares in Q4 2023, an estimated $39.
  • Newbridge Financial Services Group first reported a position in Praxis Precision Medicines in Q1 2021 and held it in 11 quarters.
  • Newbridge Financial Services Group's Praxis Precision Medicines position peaked at $1K in Q3 2021.
  • 60 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q4 2023.

Based on Newbridge Financial Services Group's 13F filing for Q4 2023, filed 28 Mar 2024.